OmicsDI
Toggle navigation
Browse
Submit Data
Databases
API
Advanced
Search
2
Results
Show all
Save search
Copy query
Show results for
Unknown
(1)
Proteomics
(1)
Organisms
Archaea
(1)
Bacteria
(1)
Betaherpesvirinae
(1)
Borrelia
(1)
Botrytis cinerea
(1)
Candida albicans
(1)
Clostridium perfringens
(1)
Eukaryota
(1)
Fungi
(1)
Hepatitis B virus
(1)
Human betaherpesvirus 5
(1)
Influenza C virus
(1)
Japanese encephalitis virus group
(1)
Miscanthus x giganteus
(1)
Mus musculus
(1)
Mycobacterium tuberculosis
(1)
Orthoflavivirus
(1)
Panicum virgatum
(1)
Rattus
(1)
Saccharomyces cerevisiae
(1)
Salmonella enterica subsp. enterica
(1)
Schizosaccharomyces
(1)
Schizosaccharomyces pombe
(1)
Severe acute respiratory syndrome coronavirus 2
(1)
Staphylococcus aureus
(1)
Streptococcus pneumoniae
(1)
Toxoplasma gondii
(1)
Tripsacum dactyloides
(1)
Trypanosoma cruzi
(1)
Viruses
(1)
Repository
pride
(1)
Tissue
Cell culture
(1)
Disease
Breast cancer
(1)
Technology Type
Mass Spectrometry
(1)
Shotgun proteomics
(1)
Publication Date
2020
(1)
Release Date
2021
(1)
Lab affiliation
Stanford University, Canary Center at Stanford for Cancer Early Detection, USA
(1)
Previous
page
1 / 1
You're on page
1
Next
page
Sort
by:
Relevance
Page size
10
Novel Aza-podophyllotoxin derivative induces oxidative phosphorylation and cell death via AMPK activation in triple-negative breast cancer.
Not available
S-EPMC7851402
|
biostudies-literature
Cite
Novel Aza-Podophyllotoxin Derivative in Triple Negative Breast Cancer
Four cell lines (MCF10A, MCF12A, MDA-MB-231, and MDA-MB-468) were treated with a novel drug candidate.
ORGANISM(S):
Homo sapiens (Human)
2020-11-09
|
PXD018929
|
Pride
Breast cancer
Drug treatment
Lc-ms/ms
Cite
Previous
page
1 / 1
You're on page
1
Next
page
Sort
by:
Relevance
Page size
10
OmicsDI
is part of the ELIXIR infrastructure
OmicsDI is an Elixir interoperability service.
Learn more ›
Tweets
